Advanced Search

Home > Journals > Panminerva Medica > Past Issues > Panminerva Medica 1998 September;40(3) > Panminerva Medica 1998 September;40(3):244-6

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEPANMINERVA MEDICA

A Journal on Internal Medicine

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,6

Frequency: Quarterly

ISSN 0031-0808

Online ISSN 1827-1898

 

Panminerva Medica 1998 September;40(3):244-6

    CASE REPORTS

Prophylaxis of cys­tine cal­cu­li by ­low ­dose of α−mercapto-pro­pi­o­nyl-gly­cine admin­is­tered eve­ry oth­er ­day

Berio A., Piazzi A.

From ­the Chair of Pediatrics, University of Genoa Institute G. Gaslini, Genoa, Italy

In a ­case of typ­i­cal cys­ti­nu­ria ­type I ­with ­left kid­ney hypo­pla­sia ­and bilat­er­al cal­cu­lo­sis, cal­cu­li ­were dis­solved by ­means of α-mer­cap­to-pro­pi­o­nyl-gly­cine ­and pro­phy­lax­is of ­the cal­cu­lo­sis ­was per­formed by ­the ­same ­drug con­tin­u­ous­ly admin­is­tered in ­two divid­ed dos­es (10-4 mg·kg-1·­day-1) ­for 9 ­years, with­out urol­i­thi­a­sis. Then, ­the α-mer­cap­to-pro­pi­o­nyl-gly­cine eve­ry oth­er ­day in ­one ­dose, 4 mg·kg-1·­day-1, ­for ­two ­years ­was admin­is­tered with­out cal­cu­lo­sis. The arbi­trary dis­con­tin­u­a­tion of ­the ­drug by ­the ­patient ­was fol­lowed ­after 6 ­months ­from a ­right uret­er­al cal­cu­lo­sis ­with tran­si­to­ry ­renal insuf­fi­cien­cy. In ­our ­case ­the admin­is­tra­tion of a ­low ­dose of α-mer­cap­to-pro­pi­o­nyl-gly­cine eve­ry oth­er ­day ­was use­ful in cys­tine cal­cu­lo­sis pro­phy­lax­is.

language: English


FULL TEXT  REPRINTS

top of page